November 1, 2012
At the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, held in Boston October 28-31, 2012, we presented exciting data covering several of the company’s therapeutic programs and delivery platforms.
THERAPEUTIC PROGRAMS
Therapeutic research highlighted recent clinical and pre-clinical work from our programs in transthyretin-mediated amyloidosis (TTR), hemophilia, hypercholesterolemia, and liver cancer. Click here for presentations.
February 8, 2012
January 1, 2012
Below is a list of historical press releases related to our ALN-PCS program for the treatment of hypercholesterolemia:
2012
04/20/2012 Alnylam Reports Positive Clinical Results for ALN-PCS 04/01/2012 Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK92011
09/26/2011 Alnylam Initiates Phase I Clinical Study of ALN-PCS 11/07/2011 Alnylam files Clinical Trial Application2010
15/03/2010 Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK92009
18/06/2009 Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK92008
12/08/2008 Alnylam and Collaborators Publish New Pre-Clinical Research on RNAi-Mediated Silencing of PCSK92007
08/10/2007 Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK92006
05/12/2006 Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 17/07/2006 Alnylam Announces Collaboration with UTSW Medical Center to Discover RNAi Therapeutics for Hypercholesterolemia
